Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy
Shoichi Iriguchi, Yutaka Yasui, Yohei Kawai, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 154

Showing 1-25 of 154 citing articles:

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Alexander Dimitri, Friederike Herbst, Joseph A. Fraietta
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 223
Engineered cellular immunotherapies in cancer and beyond
Amanda Finck, Tatiana Blanchard, Christopher P. Roselle, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 678-689
Open Access | Times Cited: 209
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Steven Μ. Albelda
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 1, pp. 47-66
Closed Access | Times Cited: 182
Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications
Jonas Cerneckis, Hongxia Cai, Yanhong Shi
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 75
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy
Matin Chehelgerdi, Fereshteh Behdarvand Dehkordi, Mohammad Chehelgerdi, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 71
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
Christopher A. Klebanoff, Smita S. Chandran, Brian M. Baker, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 12, pp. 996-1017
Open Access | Times Cited: 66
Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy
Dixuan Xue, Shan Lu, Hailing Zhang, et al.
Trends in biotechnology (2023) Vol. 41, Iss. 7, pp. 907-922
Open Access | Times Cited: 45
Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology
Ruiyu Tao, Xiaopeng Han, Xue Bai, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 31
Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?
Caroline Lonez, Eytan Breman
Cells (2024) Vol. 13, Iss. 2, pp. 146-146
Open Access | Times Cited: 21
DL4-μbeads induce T cell lineage differentiation from stem cells in a stromal cell-free system
Ashton Trotman‐Grant, Mahmood Mohtashami, Joshua de Sousa Casal, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 64
EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity
Ran Jing, Irene Scarfo, Mohamad Najia, et al.
Cell stem cell (2022) Vol. 29, Iss. 8, pp. 1181-1196.e6
Open Access | Times Cited: 62
3D bioprinted, vascularized neuroblastoma tumor environment in fluidic chip devices for precision medicine drug testing
Daniel Nothdurfter, Christian Ploner, Débora C. Coraça‐Huber, et al.
Biofabrication (2022) Vol. 14, Iss. 3, pp. 035002-035002
Open Access | Times Cited: 54
Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells
Sjoukje J. C. van der Stegen, Pieter L. Lindenbergh, Roseanna M. Petrovic, et al.
Nature Biomedical Engineering (2022) Vol. 6, Iss. 11, pp. 1284-1297
Open Access | Times Cited: 53
Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells
Tatsuki Ueda, Sara Shiina, Shoichi Iriguchi, et al.
Nature Biomedical Engineering (2022)
Open Access | Times Cited: 50
Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies
Frank Cichocki, Sjoukje J. C. van der Stegen, Jeffrey S. Miller
Blood (2022) Vol. 141, Iss. 8, pp. 846-855
Open Access | Times Cited: 49
Advancing cell-based cancer immunotherapy through stem cell engineering
Yan-Ruide Li, Zachary Spencer Dunn, Yanqi Yu, et al.
Cell stem cell (2023) Vol. 30, Iss. 5, pp. 592-610
Open Access | Times Cited: 41
Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy
Yang Zhou, Miao Li, Kuangyi Zhou, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2266-2266
Open Access | Times Cited: 40
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review
Cristina Aparicio, Carlos Acebal, Margarita González‐Vallinas
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 39
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
Zhi Pang, Manman Lu, Yu Zhang, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 29
Adoptive Cell Therapy for Nonhematologic Solid Tumors
Daniel J. Olson, Kunle Odunsi
Journal of Clinical Oncology (2023) Vol. 41, Iss. 18, pp. 3397-3407
Closed Access | Times Cited: 27
Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
Zixin Lv, Fei‐Fei Luo, Yiwei Chu
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
Human iPSC-derived CD4+ Treg-like cells engineered with chimeric antigen receptors control GvHD in a xenograft model
Hisashi Yano, Keiko Koga, Takayuki Sato, et al.
Cell stem cell (2024) Vol. 31, Iss. 6, pp. 795-802.e6
Open Access | Times Cited: 13
Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation
Ratchapong Netsrithong, Laura García-Pérez, Maria Themeli
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 12
Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics
Daniel C. Kirouac, Cole Zmurchok, Denise Morris
npj Systems Biology and Applications (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 12
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Caroline Diorio, David T. Teachey, Stephan A. Grupp
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top